To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).
To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
164
Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.
Oral administration of a matched placebo powder. Dosage: one sachet, 2-3 times daily, for 3 months.
Yifeng Yu
Nanchang, Jiangxi, China
RECRUITINGChange in Spherical Equivalent Refraction
The change in spherical equivalent refraction (SER) from baseline to each follow-up visit, measured in diopters (D). SER is calculated as the spherical power plus half of the cylindrical power. A negative change indicates an increase in myopia.
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Axial Length
The growth value of ocular axial length, measured in millimeters (mm).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Corneal Curvature
The change in corneal curvature (keratometry), measured in diopters (D).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Binocular Anisometropia
The difference in spherical equivalent refraction between the two eyes, measured in diopters (D).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Anterior Chamber Depth
The change in depth of the anterior chamber of the eye, measured in millimeters (mm).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Lens Thickness
The change in thickness of the crystalline lens, measured in millimeters (mm).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Vitreous Cavity Depth
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The change in depth of the vitreous cavity, measured in millimeters (mm)
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Far Phoria Degree
The degree of heterophoria for distance vision, measured in prism diopters (PD).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in Near Phoria Degree
The degree of heterophoria for near vision, measured in prism diopters (PD).
Time frame: Measured at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Score on the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25)
Visual quality and vision-related quality of life is assessed using the National Eye Institute Visual Function Questionnaire - 25 (NEI VFQ-25). The overall composite score ranges from 0 to 100, where a higher score represents better visual function and quality of life.
Time frame: Assessed at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Score on the Montreal Cognitive Assessment (MoCA)
Cognitive function is assessed using the Montreal Cognitive Assessment (MoCA), a widely used screening test for cognitive impairment. The total score ranges from 0 to 30, with a score of 26 or higher considered normal. As probiotic supplementation may influence cognitive function, this will be considered in the interpretation of results.
Time frame: Assessed at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Score on the Gastrointestinal Symptom Rating Scale (GSRS)
Gastrointestinal symptoms are assessed using the Gastrointestinal Symptom Rating Scale (GSRS), a validated questionnaire covering reflux, abdominal pain, indigestion, diarrhea, and constipation. Each symptom is rated on a scale from 0 (no discomfort) to 6 (very severe discomfort). A higher total or subscale score indicates more severe gastrointestinal symptoms (worse outcome). As probiotic supplementation may influence gastrointestinal function, this will be considered in the interpretation of results.
Time frame: Assessed at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Score on the World Health Organization Quality of Life Brief Version (WHOQOL-BREF)
Participant adaptation and overall quality of life are assessed using the World Health Organization Quality of Life Brief Version (WHOQOL-BREF), a validated generic quality of life instrument. It covers physical health, psychological health, social relationships, and environment domains. The total score is transformed to range from 0 to 100, where a higher score indicates a better quality of life and better adaptation. As probiotic supplementation may influence overall well-being, this will be considered in the interpretation of results.
Time frame: Assessed at baseline, 1, 3, 6, 9, 12, 13, 14, 19, and 25 months post-intervention.
Change in gut microbiota composition and diversity assessed by 16S rRNA gene sequencing
Fecal samples collected before and after intervention are analyzed using full-length 16S rRNA gene sequencing. Key metrics include changes in alpha diversity indices (e.g., Shannon Index, observed species), beta diversity (e.g., weighted/unweighted UniFrac distance), and relative abundance of specific bacterial taxa (e.g., phylum Firmicutes/Bacteroidota ratio, genus Bifidobacterium).
Time frame: Fecal samples collected at baseline, 3, 6, 12, and 25 months post-intervention for sequencing analysis.
Change in concentrations of fecal and serum metabolites
Targeted metabolomic analysis is performed on fecal and blood serum samples. Concentrations of specific metabolites (e.g., short-chain fatty acids, bile acids, or inflammatory cytokines) are measured and reported in nanomolar (nM) or picograms per milliliter (pg/mL) concentrations, as applicable.
Time frame: Fecal and blood serum samples collected at baseline, 3, 6, 12, and 25 months post-intervention for metabolite analysis.